Abstract
Variants in the MAGED2 gene cause a transient form of antenatal Bartter syndrome (aBS), characterized by severe polyhydramnios, preterm labor, and postnatal electrolyte imbalances that resolve spontaneously. This report details the first Chinese case of an extremely preterm infant (born at 27+5 weeks) with a novel MAGED2 variant (c.1426C > T, p.Arg476X) who presented with previously undocumented symptoms: transient gross hematuria and acute kidney injury (AKI). Following supportive care, clinical symptoms and renal function normalized within a month. This case expands the known phenotypic and genotypic spectrum of MAGED2-related aBS.
Introduction
Bartter syndrome encompasses a group of rare salt-losing tubulopathies. Antenatal Bartter syndrome (aBS) is particularly severe, often presenting with fetal polyuria leading to massive polyhydramnios and extreme prematurity. While most forms are chronic, mutations in MAGED2 on the X chromosome cause a unique "transient" form. In these patients, the salt-wasting symptoms are profound at birth but typically resolve within weeks as oxygenation improves postnatally.
Case Presentation
A male infant was born at 27 weeks and 5 days of gestation following a pregnancy complicated by severe polyhydramnios first detected at 24 weeks. The amniotic fluid index (AFI) remained significantly elevated above the normal range (8–24 cm) throughout the late second trimester, peaking at 66.54 cm.
Postnatally, the infant exhibited classic signs of Bartter syndrome: polyuria, severe hyponatremia, hypokalemia, and metabolic alkalosis. However, he also presented with unexpected gross hematuria and acute kidney injury (AKI), with creatinine levels peaking at 115.5 μmol/L. Despite a 30.4% loss in body weight, the infant responded well to electrolyte replacement and nutritional support. By day 14, renal function had normalized, and by one month, all electrolyte imbalances had resolved without the need for long-term medication.
Genetic Findings and Key Results
Whole-exome sequencing (WES) identified a novel hemizygous nonsense variant in MAGED2: c.1426C > T (p.Arg476X). Sanger sequencing confirmed that the variant was inherited from his asymptomatic mother.
Key findings include:
- Novel Phenotype: This is the first report linking MAGED2 variants to transient hematuria and AKI. Previously, these were not considered hallmarks of the syndrome.
- Transient Mechanism: MAGED2 is essential for salt transporter (NKCC2 and NCC) function under fetal hypoxic conditions. Postnatal normoxia likely allows for compensatory pathways, explaining the spontaneous recovery.
- Clinical Outcome: At a 1-year follow-up, the child demonstrated normal growth, development, and renal function.
Discussion and Clinical Implications
This case highlights the critical role of early genetic testing in neonatal renal failure. Identifying a MAGED2 variant allows clinicians to distinguish transient aBS from permanent forms of the disease. This knowledge prevents unnecessary invasive procedures, such as renal biopsies, and avoids overmedication with drugs like indomethacin, which can be harmful to preterm infants.
While the hematuria and AKI observed in this case were transient, they represent an expansion of the clinical spectrum for MAGED2 mutations. Future research should investigate whether these symptoms are specific to the p.Arg476X variant or are rare manifestations of the syndrome that have been previously underreported.
Conclusion
The discovery of the c.1426C > T variant in MAGED2 provides a new genetic marker for transient antenatal Bartter syndrome. This case underscores the importance of considering genetic tubulopathies in the differential diagnosis of neonatal AKI and polyuria, ensuring that extremely preterm infants receive appropriate supportive care while awaiting spontaneous recovery.
Summary updated